CClinicalTrials.gg
CompletedNCT02868021BFRUpdated Jul 24, 2019

Blood Flow Restriction Exercise Study

An interventional study of Strength testing and Short Physical Performance Battery (SPPB) in Osteoarthritis, Knee, sponsored by University of Florida. Completed at 1 site in United States. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-07-24.

Sponsored by University of Florida · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
55 Years to 80 Years
Sex
All
01

Study summary

This pilot study will investigate the effects of blood flow restriction (BFR) exercise for up to 4-6 weeks prior to total knee arthroplasty (TKA) surgery in older patients to measure clinical outcomes such as strength, lower extremity function, and pain.

Read the detailed description

The purpose of this study is to test the feasibility and efficacy of a low-resistance exercise protocol with blood flow restriction (BFR) using a tourniquet in the preoperative period of patients awaiting TKA. BFR exercise is a new exercise method that has not been studied in the perioperative period. The investigators will compare our intervention to a no-exercise group up to 4 - 6 weeks prior to surgery to determine if this type of exercise is feasible in the preoperative period and if BFR exercise will improve functional, physiological, and molecular outcomes when compared to patients without exercise.

02

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • Elderly
  • Exercise
03

In context

Osteoarthritis, Knee

3,302 studies on the registry are indexed under Osteoarthritis, Knee; 608 are open to participants now.

This study's enrollment of 12 is below the median of 70 across 2,731 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

University of Florida is the lead sponsor of 1,254 studies on the registry; 201 are open to participants now.

Of its 170 completed or terminated interventional studies of FDA-regulated products, 136 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • are scheduled for elective TKA for osteoarthritis
  • are scheduled for unilateral joint replacement surgery only
  • are able to give consent and follow instructions
  • are willing to complete up to 15 study visits

Exclusion criteria

Exclusion Criteria:

  • patients below the age of 55 years old
  • patients over the age of 80 years old
  • patients who live in a radius greater than 45 miles from the University of Florida (a feasible distance to allow for transportation to and from the clinical center for assessment visits)
  • patients with impaired cognitive function and mental disease, (e.g. diagnosis of Alzheimer's disease)
  • patients with paraplegia/extremity amputation
  • patients with end stage renal disease requiring dialysis
  • patients with uncontrolled diabetes and insulin-dependent diabetes
  • patients with uncontrolled cardiovascular disease e.g. (Classes of Heart Failure (CHF) New York Heart Association (NYHA) class 3 or higher, BP > 180/110 mmHg)
  • patients with severe pulmonary disease requiring continuous oxygen therapy
  • patients with active neoplasm
  • patients with peripheral vascular disease or deep vein thrombosis (within the last 3 years)
  • patients with structured exercise/Physical Therapy(PT)/Occupational Therapy (OT)/fitness program enrollment within 12 weeks prior to surgery and/or more than 2 hours per month on gym/fitness room exercises
  • patients with BMI greater than 40 kg/m2
  • patients with opioid use of more than 30 mg Morphine-equivalents per day
  • patients with chronic oral steroid use
  • patients with chronic anticoagulation (e.g. Plavix, Warfarin)
  • patients with planned postoperative admission to a skilled nursing/inpatient rehab facility
  • patients with ipsilateral joint disease involving hip, ankle or spine
  • neurologic or other etiology of quadriceps wasting
  • surgery within less than 4 weeks
  • patients with comorbidities that the PI judges as not suitable for the study
  • patients with a minimal mental status (MMSE) score below 24
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Placebo comparator
    NO-EX group

    Subjects allocated to the No Exercise (NO-EX) group will undergo: Strength testing, Short Physical Performance Battery (SPPB), Six-minute walk (SMW), Numerical pain scale, Self-assessed function and Six-minute walk (SMW) test. Intra-op muscle biopsies.

    Device: Strength testing · Behavioral: Short Physical Performance Battery (SPPB) · Behavioral: Six-minute walk (SMW) · Behavioral: Numerical pain scale · Behavioral: Self-assessed function · Procedure: Muscle biopsies

  • Experimental
    EX-BFR group

    Subjects allocated to the EX-BFR group will undergo baseline strength testing, Short Physical Performance Battery (SPPB), Numerical pain scale, Six-minute walk (SMW), Self-assessed function, and determination of 1 Repetition Maximum (1-RM). Blood flow restriction exercise, Borg Category Ratio 10 (Borg CR10) scale. Intra-op muscle biopsies.

    Device: Strength testing · Behavioral: Short Physical Performance Battery (SPPB) · Behavioral: Six-minute walk (SMW) · Behavioral: Numerical pain scale · Behavioral: Self-assessed function · Procedure: Muscle biopsies · Device: Determination of 1 Repetition Maximum (1-RM) · Device: Blood flow restriction exercise · Behavioral: Borg CR10 scale

Interventions

  • DeviceStrength testing

    Test the strength of subject's lower extremity muscles on the dynamometer system

  • BehavioralShort Physical Performance Battery (SPPB)

    The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.

  • BehavioralSix-minute walk (SMW)

    Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.

  • BehavioralNumerical pain scale

    Measure pain using an 11-point numerical pain scale.

  • BehavioralSelf-assessed function

    Using the Late Life Function and Disability Instrument.

  • ProcedureMuscle biopsies

    During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.

  • DeviceDetermination of 1 Repetition Maximum (1-RM)

    Following the warm-up, subjects will attempt to complete one repetition of the leg press exercise at progressively greater resistance until a full repetition can no longer be performed. The weight of the last complete unassisted repetition will be recorded as the 1-RM.

  • DeviceBlood flow restriction exercise

    Perform lower-extremity exercises (leg press, leg extension, leg curl, and calf extension) at an intensity of 30% of 1-RM with external compression applied to the proximal thigh of each leg.

  • BehavioralBorg CR10 scale

    Following each exercise session, participants will provide a rating of perceived exertion (RPE) for the session according to the Borg CR10 scale.

06

What researchers measure

Primary outcomes

  1. Changes between the two group assessed by muscle strength

    Test the strength of subject's lower extremity muscles on the dynamometer system

    Time frame: Changes from baseline (pre-op) up to 2 weeks post-op

Secondary outcomes

  1. Changes between the two group assessed by Short Physical Performance Battery (SPPB)

    SPPB is a validated test to measure lower extremity function a timed short distance walk, repeated chair stands, and balance test.

    Time frame: Changes from baseline (pre-op) up to 2 weeks post-op

  2. Changes between the two group assessed by Six-minute walk (SMW) test

    SPPB is a validated test to measure lower extremity function a timed short distance walk, repeated chair stands, and balance test.

    Time frame: Changes from baseline (pre-op) up to 2 weeks post-op

  3. Changes between the two group assessed by pain

    Measure pain using an 11-point numerical pain scale

    Time frame: Changes from baseline (pre-op) up to 2 weeks post-op

  4. Changes between the two group assessed by self-assessment outcomes

    Assessed using the Late Life Function and Disability Instrument

    Time frame: Changes from baseline (pre-op) up to 2 weeks post-op

  5. Changes between the two group assessed by biological targets on the muscle tissue

    Analysis of the muscle tissue will focus on metabolism, inflammation, autophagy, apoptosis and other mechanisms of muscular atrophy.

    Time frame: Up to 4 hours (end of surgery)

07

Study locations

1 site
  • United States, Florida UF Health
    Gainesville, Florida 32610-3003, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02868021
Lead sponsor
University of Florida
Collaborators
University of Florida Clinical and Translational Science Institute (CTSI)
Responsible party
Sponsor
First posted
Aug 16, 2016
Start date
Dec 12, 2016
Primary completion
Aug 1, 2018
Completion
Aug 1, 2018
Last update
Jul 24, 2019

Study contacts

Rene Przkora, MD
principal investigator · University of Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion